Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2004-005197-23-DE
EUCTR2004-005197-23-DE
Active, not recruiting
Not Applicable

Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem. - DME-TA

Klinik und Poliklinik für Augenheilkunde der Universität Regensburg0 sites40 target enrollmentMay 17, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsTriam-Hexal 40

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Klinik und Poliklinik für Augenheilkunde der Universität Regensburg
Enrollment
40
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 17, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Klinik und Poliklinik für Augenheilkunde der Universität Regensburg

Eligibility Criteria

Inclusion Criteria

  • •?patients with diabetes mellitus II
  • •?signs of diffuse macular edema in both eyes
  • •?indication for (re\-)GRID laser\-coagulation in both eyes
  • •?best corrected visual acuity of \>\=0,1 and \<0,5
  • •?ability to perform a micro\-perimetry\-examination
  • •?patient is able and willing to sing the informed consent and to participate in the study
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • •?macular illness other than diabetic maculopathy
  • •?previous operation in the macular region of the study eye
  • •?previous chorioretinitis or acute infection of the eye (also conjunctivitis)
  • •?glaucoma or known steroid responder
  • •?immunosuppression
  • •?pregnancy/lactation period
  • •?significant opacities, which preclude a clear view of the macular region in the study eye
  • •?other sever illness, which, in the opinion of the study doctor, precludes participation in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Intravitreal injection of methotrexate in persistent diabetic macular edemaResistant macular edema in diabetic patients.Distrubtion of retinal layers due to edema
IRCT201610098983N2Guilan University of Medical Sciences,Vice chancellor for research42
Completed
Phase 3
The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edemadiabetic macular edema
JPRN-UMIN000017037Jichi Medica University, Saitama Medical Center100
Recruiting
Phase 1
Investigating the effect of mesenchymal stem cell injection on reducing complications in patients with liver cirrhosisReducing complications of liver failure in patients with decompensated liver cirrhosis.Congenital cirrhosis (of liver)P78.81
IRCT20140911019125N11Kerman University of Medical Sciences10
Recruiting
Phase 3
The Comparison of Efficacy Between Iranian Made Ranibizumab and Imported Ranibizumab in Diabetic Patients with Macular Edema
IRCT20170303032845N1Aracell zist daru154
Active, not recruiting
Phase 1
ongterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.Choroidal neovascularisation and chronic macular edemaMedDRA version: 20.0Level: LLTClassification code 10054467Term: Macular edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 21.1Level: PTClassification code 10060823Term: Choroidal neovascularisationSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
EUCTR2013-005056-15-BEZ Gent800